*Median reduction in number of attacks with HAEGARDA vs placebo. † In a 32-week crossover study, patients ≥12 years of age with symptomatic type 1 or 2 HAE (N=90) were randomly assigned to twice-weekly therapy with HAEGARDA 40 IU/kg or 60 IU/kg. Patients initiated 16 weeks of active therapy or placebo and crossed over to placebo or active therapy for the subsequent 16 weeks. Baseline HAE attack frequency was 8.8 in the 3 months before screening for the 60 IU/kg group.2
‡The WAO Guideline for the Management of HAE states that patients should have HAE rescue medication available at all times.3 §Median reduction in rescue medication use vs placebo.
||Includes patients who were treated with 40 IU/kg and 60 IU/kg. ¶ Includes bruising, coldness, discharge, erythema, hematoma, hemorrhage, induration, edema, pain, pruritus, rash, injection-site reaction, scarring, swelling, urticaria, and warmth at the injection site. #Includes hypersensitivity, pruritus, rash, and urticaria.
SUBCUTANEOUS INJECTION SITES
HAEGARDA can be administered in any applicable subcutaneous injection site.